Dr. Beninger is a Therapeutic Area Head in Pharmacovigilance and Epidemiology at Genzyme, a Sanofi company, in Cambridge, Massachusetts, where he is responsible for supervising the global safety profile of the company’s renal, cardiovascular and cell-based therapy products.
He began his career in drug development in 1987 at the US Food and Drug Administration, first as a reviewer and manager for drugs against HIV/AIDS and opportunistic infections and then as a division director for medical devices. He joined Merck & Company in 1995 and developed experience in regulatory affairs, medical services and drug safety in the areas of anti-infective drug and biological products, vaccines, anti-diabetic drug products and oncology drug products, before joining Genzyme as vice-president of pharmacovigilance in 2006; Genzyme was acquired by Sanofi in 2011.
Dr Beninger trained in internal medicine and infectious diseases. He received his MD from UC Davis, his BA from Claremont McKenna College in Claremont, California, his MBA from St Joseph’s University in Philadelphia, Pennsylvania, and his graduate certificate in epidemiology from Tufts. He has published and spoken extensively on regulatory science, drug and vaccine safety, and pharmacovigilance, and he is a fellow of the American College of Physicians and the Infectious Disease Society of America.
He is also an Assistant Professor of Public Health & Community Medicine at Tufts University School of Medicine, where he is the Director of a new Master’s degree program in Development and Regulation of Medicines and Devices and Director of the MD/MBA and MBS/MBA Programs.